EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 ---- Phase 3 PREVAIL CVOT overall event rate ...
Palo Verde Hospital has experienced years of financial instability that have led to reduced services at the medical facility ...
Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential ...
Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...
The European Commission has approved French pharma major Sanofi’s Teizeild (teplizumab) to delay the onset of stage 3 type 1 ...
Brown County Commissioners met Wednesday afternoon, Jan. 7, to approve routine business and hear extended public comment ...
The prospect of an almost 200-foot radio communications tower atop the hill at Tower Street in Westerly, next to the iconic ...
We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...
European Commission approves Sanofi’s Teizeild to treat patients with stage 2 type 1 diabetes: Paris Tuesday, January 13, 2026, 11:00 Hrs [IST] The European Commission has appro ...
YAVNE, Israel, January12, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency's review of Anaphylm NDA ...
The FDA accepted Besremi's application for essential thrombocythemia, supported by SURPASS-ET and EXCEED-ET trial results, with a review target date of August 30, 2026. Essential thrombocythemia is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback